Cognition Therapeutics INC Form 4 insider transactions

Cognition Therapeutics Inc. reports that Chief Financial Officer John Brendan Doyle acquired 8,567 shares of common stock on May 1, 2026, through a transaction covering tax withholding obligations.

CFO John Brendan Doyle purchased 10,000 shares of Cognition Therapeutics common stock at $1.13 per share.

CEO and President Lisa Ricciardi purchased 9,175 shares of Cognition Therapeutics common stock at $1.10 per share.

Chief Medical Officer Anthony Caggiano acquired 10,000 shares of Cognition Therapeutics common stock at $1.11 per share.

Cognition Therapeutics CEO Lisa Ricciardi reported the vesting of 800,000 restricted stock units and subsequent sales to cover tax obligations.

Cognition Therapeutics' CFO, John Brendan Doyle, reported an acquisition of 200,000 restricted stock units and a subsequent disposition of shares for tax obligations.

Cognition Therapeutics' Chief Medical Officer, Anthony Caggiano, reported the acquisition of 400,000 restricted stock units and subsequent tax-related dispositions.

Cognition Therapeutics CEO Lisa Ricciardi acquired 75,000 shares through PSU vesting and disposed of 23,400 shares for tax obligations.

Cognition Therapeutics' Chief Medical Officer, Anthony Caggiano, acquired 65,000 shares of common stock through PSU vesting, while 20,280 shares were withheld for tax obligations.

Cognition Therapeutics' Chief Financial Officer, John Brendan Doyle, reported the vesting of performance stock units and subsequent tax-related share disposition.

Aaron G.L. Fletcher, a Director and 10% owner of Cognition Therapeutics, exercised stock options to acquire 7,729 shares of common stock.

Cognition Therapeutics' Chief Medical Officer, Anthony Caggiano, reported the acquisition of 65,000 shares of common stock through the vesting of performance stock units, alongside a disposition of 20,281 shares for tax withholding.

Cognition Therapeutics' Chief Financial Officer, John Brendan Doyle, acquired 30,000 shares through performance stock unit vesting and disposed of 9,360 shares for tax obligations.

Cognition Therapeutics CEO Lisa Ricciardi reported the vesting of 75,000 performance stock units and the subsequent disposition of 23,400 shares for tax obligations, increasing her direct beneficial ownership to 938,666 shares.

Cognition Therapeutics Inc. Director Jack A. Khattar was granted 34,000 restricted stock units (RSUs) on June 18, 2025, increasing his beneficial ownership to 48,500 shares.

Cognition Therapeutics Inc. Director Peggy Wallace was granted 34,000 restricted stock units, increasing her beneficial ownership to 86,461 shares.

Ellen B. Richstone, a Director at Cognition Therapeutics Inc., was granted 34,000 restricted stock units, increasing her direct beneficial ownership to 58,500 shares.

A recent SEC Form 4 filing reveals that Brett P. Monia, a Director at Cognition Therapeutics Inc. (CGTX), was granted 34,000 Restricted Stock Units (RSUs) as part of his compensation.

Leslie W. Kreis, a Director and 10% owner of Cognition Therapeutics Inc., reported the acquisition of 34,000 restricted stock units (RSUs) and detailed significant indirect beneficial ownership through various Bios and Cavu entities.

A recent SEC Form 4 filing reveals that Cognition Therapeutics Inc. Director Aaron G.L. Fletcher was granted 34,000 restricted stock units (RSUs) and details his significant indirect beneficial ownership through various Bios Equity Partners entities.

John Brendan Doyle, CFO of Cognition Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations related to vesting restricted stock units.

CEO Lisa Ricciardi reports disposition of shares to cover tax obligations related to vesting of restricted stock units.

Anthony Caggiano, Chief Medical Officer of Cognition Therapeutics, reports the disposal of shares to cover tax withholding obligations related to vesting restricted stock units.

Chief Financial Officer of Cognition Therapeutics, John Brendan Doyle, reports the disposal of 1,723 common stock shares to cover tax withholding obligations.

Chief Medical Officer Anthony Caggiano of Cognition Therapeutics Inc. reports acquiring 295,000 shares of common stock through a restricted stock unit (RSU) award, while also having shares withheld to cover tax obligations.

John Brendan Doyle, CFO of Cognition Therapeutics, acquired 295,000 shares of common stock on February 4, 2025, through restricted stock units.

CEO Lisa Ricciardi reports acquisition and disposal of Cognition Therapeutics (CGTX) stock, including purchases, tax withholding, and vesting of restricted stock units.

Leslie W. Kreis, along with associated entities, reports the acquisition of shares and options in Cognition Therapeutics, Inc. related to restricted stock units.

Director Aaron G.L. Fletcher reports the acquisition of stock options and restricted stock units in Cognition Therapeutics, along with adjustments to beneficial ownership held through various entities.

Director Peggy Wallace acquired 8,500 shares of common stock and options in Cognition Therapeutics on June 7, 2024.